Skip Navigation


Rheumatology Advance Access originally published online on May 31, 2008
Rheumatology 2008 47(8):1261; doi:10.1093/rheumatology/ken211
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow All Versions of this Article:
47/8/1261    most recent
ken211v1
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Müller-Ladner, U.
PubMed
Right arrow Articles by Müller-Ladner, U.
Related Collections
Right arrow Rheumatoid Arthritis
Right arrow Spondylarthropathies
Right arrow Experimental Arthritis
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© The Author 2008. Published by Oxford University Press on behalf of the British Society for Rheumatology. All rights reserved. For Permissions, please email: journals.permissions@oxfordjournals.org

BOOK REVIEWS

CONTEMPORARY TARGETED THERAPIES IN RHEUMATOLOGY, Edited by J. S. Smolen and P. E. Lipsky.

CONTEMPORARY TARGETED THERAPIES IN RHEUMATOLOGY, Edited by J. S. Smolen and P. E. Lipsky. £145.00. Informa Healthcare, 2007. 636 pp. ISBN: 9-781841-844848.

U. Müller-Ladner

The first 10% of the full text of this article appears below.

In the past decade, initiated by the introduction of TNF and IL-1 inhibition, the evolution of therapeutic strategies in rheumatology has left the area of unspecific targeting of pro-inflammatory . . . [Full Text of this Article]


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?